<SEC-DOCUMENT>0001564590-21-030940.txt : 20210601
<SEC-HEADER>0001564590-21-030940.hdr.sgml : 20210601
<ACCEPTANCE-DATETIME>20210601070932
ACCESSION NUMBER:		0001564590-21-030940
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20210601
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210601
DATE AS OF CHANGE:		20210601

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alkermes plc.
		CENTRAL INDEX KEY:			0001520262
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				981007018
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35299
		FILM NUMBER:		21982933

	BUSINESS ADDRESS:	
		STREET 1:		CONNAUGHT HOUSE
		STREET 2:		1 BURLINGTON ROAD
		CITY:			DUBLIN 4
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		00-353-1-772-8000

	MAIL ADDRESS:	
		STREET 1:		CONNAUGHT HOUSE
		STREET 2:		1 BURLINGTON ROAD
		CITY:			DUBLIN 4
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANTLER SCIENCE TWO PLC
		DATE OF NAME CHANGE:	20110804

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Antler Science Two Ltd
		DATE OF NAME CHANGE:	20110509
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>alks-8k_20210601.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-06-01T00:14:59.0716536+00:00 -->
<!-- Version            : 5.0.1.617 -->
<!-- Package ID         : dbfe61a27709401ca84cb578ac3c8415 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:alks="http://www.alkermes.com/20210601" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
alks-8k_20210601.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001520262_20210601_20210601">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000003" name="dei:EntityRegistrantName" contextRef="C_0001520262_20210601_20210601">Alkermes plc.</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:EntityCentralIndexKey" contextRef="C_0001520262_20210601_20210601">0001520262</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="alks-20210601.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001520262_20210601_20210601">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001520262</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-06-01</xbrli:startDate>
					<xbrli:endDate>2021-06-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="Background-color:#FFFFFF;margin-bottom:0pt;border-top:Double 2.25pt;padding-top:1pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Washington, D.C. 20549</span></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001520262_20210601_20210601">8-K</ix:nonNumeric></span></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">CURRENT REPORT<br />PURSUANT TO SECTION 13 OR 15(d) OF THE</span></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">SECURITIES EXCHANGE ACT OF 1934</span></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Date of Report (Date of earliest event reported): <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001520262_20210601_20210601" format="ixt:datemonthdayyearen">June 1, 2021</ix:nonNumeric></span></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">ALKERMES PUBLIC LIMITED COMPANY</span></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">(Exact name of registrant as specified in its charter)</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;width:28.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001520262_20210601_20210601" format="ixt-sec:edgarprovcountryen">Ireland</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;width:39.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityFileNumber" contextRef="C_0001520262_20210601_20210601">001-35299</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:29.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001520262_20210601_20210601">98-1007018</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:28.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;width:39.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:29.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:28.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of incorporation)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="top" style="background-color:#FFFFFF;width:39.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:29.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;width:42.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:16.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;width:41.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="background-color:#FFFFFF;width:42.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="top" style="width:41.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="7" valign="top" style="background-color:#FFFFFF;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine1" contextRef="C_0001520262_20210601_20210601">Connaught House</ix:nonNumeric>, <ix:nonNumeric id="F_000010" name="dei:EntityAddressAddressLine2" contextRef="C_0001520262_20210601_20210601">1 Burlington Road</ix:nonNumeric></p></td>
</tr>
<tr>
<td colspan="7" valign="top" style="background-color:#FFFFFF;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000011" name="dei:EntityAddressCityOrTown" contextRef="C_0001520262_20210601_20210601">Dublin 4</ix:nonNumeric>, <ix:nonNumeric id="F_000012" name="dei:EntityAddressCountry" contextRef="C_0001520262_20210601_20210601" format="ixt-sec:countrynameen">Ireland</ix:nonNumeric> <ix:nonNumeric id="F_000013" name="dei:EntityAddressPostalZipCode" contextRef="C_0001520262_20210601_20210601">D04 C5Y6</ix:nonNumeric></p></td>
</tr>
<tr>
<td colspan="7" valign="top" style="background-color:#FFFFFF;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Registrant's telephone number, including area code: + <ix:nonNumeric id="F_000014" name="dei:CityAreaCode" contextRef="C_0001520262_20210601_20210601">353</ix:nonNumeric>-<ix:nonNumeric id="F_000015" name="dei:LocalPhoneNumber" contextRef="C_0001520262_20210601_20210601">1-772-8000</ix:nonNumeric></span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="font-style:italic;Background-color:#FFFFFF;">see </span><span style="Background-color:#FFFFFF;">General Instruction A.2. below):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100.22%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;width:2.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:WrittenCommunications" contextRef="C_0001520262_20210601_20210601" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:96.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:2.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:96.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:2.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:SolicitingMaterial" contextRef="C_0001520262_20210601_20210601" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:96.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:2.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:96.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:2.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:PreCommencementTenderOffer" contextRef="C_0001520262_20210601_20210601" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:96.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:2.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:96.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;width:2.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0001520262_20210601_20210601" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="background-color:#FFFFFF;width:1.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;width:96.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:10pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:33.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top" style="width:2.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:19.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="top" style="width:2.82%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:41.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style="width:33.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:Security12bTitle" contextRef="C_0001520262_20210601_20210601">Ordinary shares, $0.01 par value</ix:nonNumeric></p></td>
<td valign="top" style="width:2.82%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:19.74%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:TradingSymbol" contextRef="C_0001520262_20210601_20210601">ALKS</ix:nonNumeric></p></td>
<td valign="top" style="width:2.82%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:41.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:SecurityExchangeName" contextRef="C_0001520262_20210601_20210601" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:10pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:10pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:33.24%;"></td>
<td style="width:33.24%;"></td>
<td style="width:33.53%;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:10pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:10pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;line-height:10pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000005" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001520262_20210601_20210601" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:10pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:10pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:10pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:10pt;text-indent:0%;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.01 Other Events. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 1, 2021, Alkermes plc issued a press release announcing that the U.S. Food and Drug Administration has approved LYBALVI<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> (olanzapine and samidorphan) for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. The press release is attached hereto as Exhibit 99.1 and is incorporated by reference in this Item 8.01.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="PRESS_RELEASE_FINSTMNTS_AND_EXHIBITS">Item&#160;9.01 Financial Statements and Exhibits.<span style="font-weight:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)&#160;Exhibits </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:10%;"></td>
<td style="width:2%;"></td>
<td style="width:88%;"></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="FIS_UNIDENTIFIED_TABLE_2">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; &#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; &#160;</p></td>
</tr>
<tr>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit </p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; &#160;</p></td>
<td valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; &#160;</p></td>
</tr>
<tr>
<td valign="bottom" style=" border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">No. </p></td>
<td valign="bottom" style=" border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; &#160;</p></td>
<td valign="bottom" style=" border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description </p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;line-height:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;line-height:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle">
<p style="text-align:justify;margin-bottom:0pt;line-height:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1 </p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160; &#160;</p></td>
<td valign="middle">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="alks-ex991_15.htm"><span style="text-decoration:none;">Press release issued by Alkermes plc dated June 1, 2021.</span></a></p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURE">SIGNATURE </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:58.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="top" style="width:41.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ALKERMES PLC</p></td>
</tr>
<tr>
<td valign="top" style="width:58.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="top" style="width:41.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:58.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: June 1, 2021</p></td>
<td valign="top" style="width:3.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" style="width:0.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:36.72%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David J. Gaffin</p></td>
</tr>
<tr>
<td valign="top" style="width:58.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:36.72%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David J. Gaffin</p></td>
</tr>
<tr>
<td valign="top" style="width:58.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:36.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Secretary</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>alks-ex991_15.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
alks-ex991_15.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">Alkermes Contacts: </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For Investors: <font style="margin-left:36pt;">Sandy Coombs, +1 781 609 6377</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:38.46%;text-indent:7.69%;color:#auto;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For Media:&nbsp;&nbsp;<font style="margin-left:36pt;">Marisa Borgasano, +1 781 609 6659</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Alkermes Announces FDA Approval of LYBALVI&#8482; for the Treatment of Schizophrenia and Bipolar I Disorder</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_Hlk54612699"></a>&#8212; New Oral Medication Offers Established Antipsychotic Efficacy of Olanzapine With Less Weight Gain &#8212;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8212; Commercial Launch Planned for Fourth Quarter 2021 &#8212;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_Hlk54612684"></a>&#8212; Company to Host Investor Conference Call Today at 8:30 a.m. ET&#160;&#8212;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk54612728"></a><a name="_Hlk72841852"></a><a name="_Hlk56088023"></a><a name="_Hlk73168281"></a><a name="_Hlk56088040"></a><a name="_Hlk54704783"></a>DUBLIN,&#160;June 1, 2021<font style="font-weight:normal;"> --&#160;</font><font style="color:#auto;text-decoration:underline;font-weight:normal;">Alkermes plc</font><font style="font-weight:normal;"><a name="_Hlk72841852"></a>&#160;(Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has <a name="_Hlk56088023"></a>approved LYBALVI&#8482; (olanzapine and samidorphan)<a name="_Hlk73168281"></a><a name="_Hlk56088040"></a> for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate<a name="_Hlk54704783"></a>. LYBALVI is a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic agent, and samidorphan, a new chemical entity.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk55892894"></a>&#8220;Schizophrenia and bipolar I disorder are complex, chronic diseases and there remains a persistent need for new medications with proven efficacy and safety. Olanzapine, a highly-efficacious atypical antipsychotic, is associated with significant side effects, including weight gain, that may impact patients&#8217; treatment experiences and limit its use,&#8221; said <font style="color:#000000;">Ren&#233; S. Kahn, M.D., Ph.D., Esther and Joseph Klingenstein&#160;Professor &amp; Chair, Department of Psychiatry and&#160;Behavioral Health System at the Icahn School of Medicine at Mount&#160;Sinai. </font>&#8220;With the efficacy of olanzapine and evidence of less weight gain in patients with schizophrenia, LYBALVI brings a welcome new addition to our medication arsenal.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk55978598"></a><a name="_Hlk55978598"></a>&#8220;LYBALVI represents an important new treatment option for adults with schizophrenia or bipolar I disorder, their clinicians and caregivers, and reflects Alkermes&#8217; commitment to developing new therapies that support patient-centered care,&#8221; said Richard Pops, Chairman and Chief Executive Officer at Alkermes. &#8220;We share this accomplishment with our employees and the many researchers, advocates, clinicians and patients who have been essential to the LYBALVI development program since its inception. Our existing commercial capabilities and presence in the antipsychotic market&#160;with ARISTADA<font style="Background-color:#FFFFFF;color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></font> provide an important foundation for the commercialization of LYBALVI, and we look forward to making this new medicine available to patients and clinicians later this year.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ENLIGHTEN clinical development program, LYBALVI demonstrated antipsychotic efficacy, safety and tolerability, including statistically significantly less weight gain than olanzapine in patients with schizophrenia in the ENLIGHTEN-2 study. Results from the ENLIGHTEN program&#8217;s pivotal ENLIGHTEN-1 efficacy study and ENLIGHTEN-2 weight study have been published in peer-reviewed journals<sup style="font-size:85%;line-height:120%;vertical-align:top">1,2</sup> and are included in the approved labeling for LYBALVI. The FDA approved LYBALVI under the 505(b)(2) regulatory pathway based on data from 27 clinical studies, including 18 studies evaluating LYBALVI and nine studies evaluating samidorphan alone, and the FDA&#8217;s findings of safety and effectiveness of olanzapine in the treatment of bipolar I disorder and schizophrenia. Data suggest that olanzapine-associated weight gain is disease independent.<sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup> </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk55904196"></a><a name="_Hlk54612807"></a>&#8220;People living with schizophrenia or bipolar I disorder must evaluate both efficacy and tolerability when making treatment decisions,&#8221; said Paul Gionfriddo, President and CEO of Mental Health America (MHA). &#8220;We are grateful that companies like Alkermes are driven to continue developing new treatment options in psychiatry that seek to address unmet needs of our community and we applaud the FDA for considering the experiences of individuals living with these conditions.&#8221;  </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alkermes expects to make LYBALVI available for patients in the fourth quarter of 2021. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk54612913"></a><font style="text-decoration:underline;">Conference Call</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alkermes will host a conference call for analysts and investors on </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tuesday</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, June </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2021 at 8:30 a.m. ET (1:30 p.m. BST). </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The webcast may be accessed on the Investors section of Alkermes&#8217; website at </font><font style="text-decoration:underline;">www.alkermes.com</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. To participate in the question and answer session, please dial in to the conference call, which may be accessed by dialing +1 877-407-2988 for U.S. callers and +1 201-389-0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes&#8217; website or by dialing +1 877-660-6853 for U.S. callers and +1 201-612-7415 for international callers, using replay access code </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13719944</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The conference call replay will be available from </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11:30 a.m. ET (4:30 p.m. BST) on </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tuesday</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, June </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2021, through </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tuesday</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, June </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2021.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">About Schizophrenia</font><font style="font-weight:normal;">&#160;<br />Schizophrenia is a serious brain disorder marked by positive symptoms (hallucinations and delusions, disorganized speech and thoughts, and agitated or repeated movements) and negative symptoms (depression, blunted emotions and social withdrawal).<sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup>&#160;Schizophrenia affects approximately 1.1% of the U.S. population.<sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup>&#160;</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:2pt;margin-top:2pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">About Bipolar I Disorder</font><font style="font-weight:normal;"><br />Bipolar disorder is a brain disorder that is marked by extreme changes in a person&#8217;s mood, energy and ability to function. Individuals with this brain disorder may experience debilitating changes in mood&#160;from extreme highs (mania) to extreme lows (depression).</font><font style="color:#000000;font-weight:normal;"> </font><font style="font-weight:normal;">Bipolar I disorder is characterized by the occurrence of at least one manic episode, with or without the occurrence of a major depressive episode, and affects approximately one percent of the adult population in&#160;the United States&#160;in any given year.<sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">About the ENLIGHTEN Clinical Development Program</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The ENLIGHTEN clinical development program for LYBALVI includes two key studies in patients with schizophrenia: ENLIGHTEN-1 and ENLIGHTEN-2. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">ENLIGHTEN-1 evaluated the antipsychotic efficacy, safety and tolerability of LYBALVI compared to placebo over four weeks in 403 patients experiencing an acute exacerbation of schizophrenia. This study met its prespecified primary endpoint, with LYBALVI demonstrating </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) scores compared to placebo (p&lt;0.001). An olanzapine comparator arm was also included, which achieved similar improvements from baseline PANSS scores compared to placebo (p=0.004). The most common adverse events (AEs) for both the LYBALVI and olanzapine treatment groups were weight gain, somnolence and dry mouth.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">ENLIGHTEN-2 evaluated the weight gain profile of LYBALVI compared to olanzapine over six months in 561 patients with stable schizophrenia. This study met its prespecified co-primary endpoints, demonstrating both a lower mean percent weight gain from baseline at six months compared to the olanzapine group (p=0.003) and a lower proportion of patients who gained 10% or more of their baseline body weight at six months compared to the olanzapine group (p=0.003).&#160;The most common AEs reported in the LYBALVI treatment group were weight gain, somnolence and dry mouth; the most common AEs reported in the olanzapine treatment group were weight gain, somnolence and increased appetite.&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The program also included supportive studies to evaluate the pharmacokinetic and metabolic profile and long-term safety of LYBALVI, and pharmacokinetic bridging studies </font><font style="Background-color:#FFFFFF;color:#1C1C1C;">comparing LYBALVI and </font>ZYPREXA<font style="Background-color:#FFFFFF;color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></font> (olanzapine).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">About LYBALVI&#8482; (olanzapine and samidorphan)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> LYBALVI (olanzapine and samidorphan) is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. LYBALVI is composed of olanzapine, an established antipsychotic agent, co-formulated with samidorphan, a new chemical entity, in a single bilayer tablet. LYBALVI will be available in<font style="Background-color:#FFFFFF;"> fixed dosage strengths composed of 10 mg of samidorphan and 5 mg, 10 mg, 15 mg or 20 mg of olanzapine.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INDICATIONS and IMPORTANT SAFETY INFORMATION FOR LYBALVI&#8482; (olanzapine and samidorphan)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INDICATIONS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LYBALVI is indicated for the treatment of:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Schizophrenia in adults</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Bipolar I disorder in adults</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;">-</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;">-</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Maintenance monotherapy treatment </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IMPORTANT SAFETY INFORMATION</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.68%;">
<tr>
<td style="width:99.68%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 1.5pt #000000; border-bottom:solid 1.5pt #000000; border-left:solid 1.5pt #000000; border-right:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LYBALVI is not approved for the treatment of patients with dementia-related psychosis.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contraindications: <font style="font-weight:normal;">LYBALVI is contraindicated in p</font><font style="color:#000000;font-weight:normal;">atients:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Who are using opioids </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:12pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><a name="_Hlk70667654"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"><a name="_Hlk70667654"></a>Who are undergoing acute opioid withdrawal </font></p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If LYBALVI is administered with lithium or valproate, refer to the lithium or valproate Prescribing Information for the contraindications for these products. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cerebrovascular Adverse Reactions, Including Stroke in Elderly Patients with Dementia-Related Psychosis:<font style="font-weight:normal;">&nbsp;&nbsp;Cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack), including fatalities, were reported in patients in trials of olanzapine in elderly patients with dementia-related psychosis. In placebo-controlled trials, there was a significantly higher incidence of cerebrovascular adverse reactions in patients treated with olanzapine compared to patients treated with placebo. LYBALVI is not approved for the treatment of patients with dementia-related psychosis.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;"><a name="_Hlk70665760"></a>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Precipitation of Severe Opioid Withdrawal in Patients who are Physiologically Dependent on Opioids: <font style="font-weight:normal;"> Samidorphan, an opioid antagonist that is a component of LYBALVI, can precipitate opioid withdrawal in patients who are dependent on opioids, which can lead to an opioid withdrawal syndrome, sometimes requiring hospitalization. Therefore, LYBALVI is contraindicated in patients who are using opioids or undergoing acute opioid withdrawal. Prior to initiating LYBALVI, there should be at least a 7-day opioid-free interval from last use of short-acting opioids, and at least a 14-day opioid-free interval from the last use of long-acting opioids.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vulnerability to Life-Threatening Opioid Overdose:&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risk of Opioid Overdose from Attempts to Overcome Samidorphan Blockade</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attempting to overcome LYBALVI&#8217;s opioid blockade with high or repeated doses of exogenous opioids could lead to life-threatening or fatal opioid intoxication (e.g., respiratory arrest, circulatory collapse), particularly if LYBALVI therapy is interrupted or discontinued subjecting the patient to high levels of unopposed opioid agonist as the samidorphan blockade wanes. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In emergency situations, if a LYBALVI-treated patient requires opioid treatment as part of anesthesia or analgesia, discontinue LYBALVI. Opioids should be administered by properly trained individual(s) and patient should be continuously monitored in a setting equipped and staffed for cardiopulmonary resuscitation.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Risk of Resuming Opioids in Patients with Prior Opioid Use</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients with a history of chronic opioid use prior to treatment with LYBALVI may have decreased opioid tolerance if LYBALVI therapy is interrupted or discontinued. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Neuroleptic Malignant Syndrome (NMS): <font style="font-weight:normal;">NMS, a potentially fatal symptom complex, has been reported with administration of antipsychotic drugs. NMS may cause hyperpyrexia, muscle rigidity, delirium, and autonomic instability. Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.</font><font style="color:#333333;font-weight:normal;"> </font><font style="font-weight:normal;">If NMS is suspected, immediately discontinue LYBALVI and provide intensive symptomatic treatment and monitoring.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): <font style="font-weight:normal;">A potentially fatal condition, DRESS has been reported with exposure to olanzapine, a component of LYBALVI. Symptoms include a cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, fever, and/or lymphadenopathy with systemic complications such as hepatitis, nephritis, pneumonitis, myocarditis, and/or pericarditis. If DRESS is suspected, discontinue LYBALVI. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Metabolic Changes: <font style="font-weight:normal;">Atypical antipsychotic drugs have been associated with metabolic changes including: </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Hyperglycemia and diabetes mellitus<font style="font-style:normal;">:&nbsp;&nbsp;Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Dyslipidemia<font style="font-style:normal;">:&nbsp;&nbsp;Antipsychotics have caused adverse alterations in lipids. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Weight gain<font style="font-style:normal;">:&nbsp;&nbsp;Weight gain has been observed with use of antipsychotics.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assess fasting glucose and lipids when initiating LYBALVI and monitor periodically.  Monitor weight at baseline and frequently thereafter.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tardive Dyskinesia (TD):&#160;<font style="color:#333333;font-weight:normal;"> </font><font style="font-weight:normal;">Risk of developing TD (a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements) and the likelihood that it will become irreversible increases with duration of treatment and the cumulative dose. The risk appears to be highest among the elderly, especially elderly women, but it is not possible to predict which patients are likely to develop TD. The syndrome can develop after a relatively brief treatment period, even at low doses, or after treatment discontinuation. LYBALVI should be prescribed in a manner that most likely reduces the risk of TD. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For chronic treatment, use the lowest dose and the shortest duration of treatment producing a satisfactory clinical response. If signs and symptoms of TD appear, drug discontinuation should be considered. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Orthostatic Hypotension and Syncope: <font style="font-weight:normal;">Atypical antipsychotics cause orthostatic hypotension and syncope. The risk is greatest during initial dose titration and when increasing the dose. </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">Monitor orthostatic vital signs in patients who are vulnerable to hypotension, patients with known cardiovascular disease, and patients with cerebrovascular disease.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Falls: <font style="font-weight:normal;">LYBALVI may cause somnolence, postural hypotension, and motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries. Complete fall risk assessment upon initiating treatment and recurrently for patients with diseases, conditions, or medications that could exacerbate these effects.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leukopenia, Neutropenia, and Agranulocytosis:<font style="font-weight:normal;"> Leukopenia and neutropenia have been reported during treatment with antipsychotics, including LYBALVI.&nbsp;&nbsp;Agranulocytosis (including fatal cases) has been reported with other agents in this class. Monitor patients with a history of significantly low white blood count (WBC) or absolute neutrophil count (ANC) or drug-induced leukopenia/neutropenia; perform a complete blood cell count (CBC) frequently during the first few months of therapy. Discontinue LYBALVI at the first sign of a clinically significant decline in WBC and in patients with severe neutropenia.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dysphagia:<font style="font-weight:normal;"> Esophageal dysmotility and aspiration have been associated with antipsychotic drug use, including LYBALVI. Use caution in patients at risk for aspiration.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Seizures:<font style="font-weight:normal;"> LYBALVI may cause seizures. Use caution in patients with a history of seizures or with conditions that lower the seizure threshold.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Potential for Cognitive and Motor Impairment: <font style="font-weight:normal;">LYBALVI may cause somnolence, impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including motor vehicles, until they are certain that LYBALVI does not affect them adversely.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Body Temperature Dysregulation: <font style="font-weight:normal;">Atypical antipsychotics may disrupt the body&#8217;s ability to reduce core body temperature. Use LYBALVI with caution in patients who may exercise strenuously, may be exposed to extreme heat, receive concomitant medication with anticholinergic activity, or are subject to dehydration.</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anticholinergic (Antimuscarinic) Effects<font style="font-weight:normal;">: Olanzapine, a component of LYBALVI, was associated with constipation, dry mouth, and tachycardia, all adverse reactions possibly related to cholinergic antagonism. Use LYBALVI with caution in patients with a current diagnosis or prior history of urinary retention, clinically significant prostatic hypertrophy, constipation, or a history of paralytic ileus or related conditions.&nbsp;&nbsp;The risk for severe adverse reactions (including fatalities) was increased with concomitant use of anticholinergic medications.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hyperprolactinemia:<font style="font-weight:normal;"> As with other drugs that antagonize dopamine D2 receptors, olanzapine, a component of LYBALVI, elevates prolactin levels.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactin-elevating compounds. Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Associated with Combination Treatment with Lithium or Valproate: <font style="font-weight:normal;"> If LYBALVI is administered with lithium or valproate, refer to the lithium or valproate Prescribing Information for a description of the risks for these products including, but not limited to, the warnings and precautions for lithium or valproate.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ADVERSE REACTIONS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Most common adverse reactions (incidence &#8805;5% and at least twice that of placebo) were:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Schizophrenia (LYBALVI):<font style="font-style:normal;"> weight increased, somnolence, dry mouth, and headache</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Bipolar I Disorder, Manic or Mixed Episodes (olanzapine):<font style="font-style:normal;"> asthenia, dry mouth, constipation, increased appetite, somnolence, dizziness, tremor </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Bipolar I Disorder, Manic or Mixed Episodes, adjunct to Lithium or Valproate (olanzapine):<font style="font-style:normal;"> dry mouth, dyspepsia, weight gain, increased appetite, dizziness, back pain, constipation, speech disorder, increased salivation, amnesia, paresthesia </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concomitant Medication: <font style="font-weight:normal;color:#000000;"> </font><font style="font-weight:normal;">Concomitant use of LYBALVI is not recommended with strong CYP3A4 inducers, levodopa and dopamine agonists, and opioid agonists. Consider dosage reduction of olanzapine component of LYBALVI when using with strong CYP1A2 inhibitors. </font></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">Consider dosage increase of olanzapine component of LYBALVI with CYP1A2 inducers.&nbsp;&nbsp;Use caution with diazepam, alcohol, other CNS acting drugs, or in patients receiving medication having anticholinergic (antimuscarinic) effects.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Monitor blood pressure and reduce dosage of antihypertensive drug in accordance with its approved product labeling.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pregnancy: <font style="font-weight:normal;">May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure. Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during treatment with LYBALVI. Inform that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to LYBALVI during pregnancy.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">To report SUSPECTED ADVERSE REACTIONS, contact Alkermes at 1-888-235-8008 or FDA at 1-800-FDA-1088 or <font style="text-decoration:underline;color:#000000;">www.fda.gov/medwatch</font>.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Please see accompanying full <font style="text-decoration:underline;">Prescribing Information</font>, including Boxed Warning, for LYBALVI.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk71107761"></a><font style="text-decoration:underline;">About&#160;Alkermes plc<br /><a name="_Hlk71107761"></a></font><font style="font-weight:normal;">Alkermes plc&#160;is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in&#160;Dublin, Ireland,&#160;Alkermes plc&#160;has an R&amp;D center in&#160;Waltham,&#160;Massachusetts; a research and manufacturing facility in Athlone,&#160;Ireland; and a manufacturing facility in&#160;Wilmington,&#160;Ohio. For more information, please visit Alkermes&#8217; website at&#160;</font><font style="text-decoration:underline;font-weight:normal;">www.alkermes.com</font><font style="font-weight:normal;">.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk54612938"></a><font style="text-decoration:underline;">Note Regarding Forward-Looking Statements<br /></font><font style="font-weight:normal;">Certain statements set forth in this press release constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the potential therapeutic and commercial value of LYBALVI for the treatment of adults with schizophrenia and the treatment of adults with bipolar I disorder; the company&#8217;s expectations regarding commercial activities, including the company&#8217;s ability to leverage its existing commercial capabilities for the commercialization of LYBALVI and timing of when the company expects to make LYBALVI available for patients. The company cautions that forward-looking statements are inherently uncertain. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: whether the clinical results for LYBALVI will be predictive of real-world results; unexpected costs or delays in the commercial launch of LYBALVI; whether LYBALVI will be commercialized successfully; whether third party payers will cover or reimburse LYBALVI for the treatment of adults with schizophrenia and the treatment of adults with bipolar I disorder; unanticipated impacts of the COVID-19 pandemic on the operations of the company; potential changes in the cost, scope and duration of the LYBALVI development and regulatory program; whether LYBALVI could be shown to be ineffective or unsafe; and those risks and uncertainties described under the heading &#8220;Risk Factors&#8221; in the company&#8217;s Annual Report on Form 10-K for the year ended&#160;Dec. 31, 2020 and in subsequent filings made by the company with the&#160;U.S. Securities and Exchange Commission&#160;(&#8220;SEC&#8221;), which are available on the&#160;SEC&#8217;s&#160;website at&#160;</font><font style="color:#auto;text-decoration:underline;font-weight:normal;">www.sec.gov</font><font style="font-weight:normal;">. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LYBALVI&#8482; is a trademark, and ARISTADA<font style="Background-color:#FFFFFF;color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></font> is a registered trademark, of Alkermes Pharma Ireland Limited. ZYPREXA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>&#160;is a registered trademark of Eli Lilly &amp; Company. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup>Potkin et al. Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study.&#160;<font style="font-style:italic;">J Clin Psych</font>, 2020;81(2):19m12769.&#160; </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">https://doi.org/10.4088/JCP.19m12769</font>  </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup> Correll et al. Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study. <font style="font-style:italic;">Am J Psychiatry</font>, 2020;(<font style="Background-color:#FFFFFF;">177)12:1168-1178. </font><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup><font style="text-decoration:underline;">https://doi.org/10.1176/appi.ajp.2020.19121279</font> </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup> Zyprexa US Prescribing Information. Indianapolis, IN: Eli Lilly and Company. <font style="text-decoration:underline;">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020592s074,021086s048,021253s061lbl.pdf</font>  </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">4 </sup>American Psychiatric Association. Schizophrenia Spectrum and Other Psychiatric Disorders.&#160;<font style="font-style:italic;">Diagnostic and Statistical Manual of Mental Disorders</font>.&#160;5<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>&#160;ed.&#160;Washington, DC:&#160;American Psychiatric Publishing; 2013.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk71281216"></a><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup><a name="_Hlk71281216"></a><sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;</sup>Cloutier M. Journal of Clinical Psychiatry. 2016 Jun; 77(6): 764-71. <font style="text-decoration:underline;">https://www.psychiatrist.com/jcp/schizophrenia/economic-burden-schizophrenia-united-states-2013/</font>  </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">&#160;</sup>Merikangas et al. Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication.&#160;<font style="font-style:italic;">Arch Gen Psychiatry</font>, 2007 May; 64(5): 543-552.&#160;<font style="text-decoration:underline;">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1931566/</font> &#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>alks-20210601.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-26T15:40:09.4314437+00:00 -->
<!-- Version            : 5.0.1.617 -->
<!-- Package ID         : dbfe61a27709401ca84cb578ac3c8415 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:alks="http://www.alkermes.com/20210601" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.alkermes.com/20210601" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.alkermes.com/20210601/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alks-20210601_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alks-20210601_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>alks-20210601_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-26T15:40:09.4314437+00:00 -->
<!-- Version            : 5.0.1.617 -->
<!-- Package ID         : dbfe61a27709401ca84cb578ac3c8415 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol(s)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>alks-20210601_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-26T15:40:09.4314437+00:00 -->
<!-- Version            : 5.0.1.617 -->
<!-- Package ID         : dbfe61a27709401ca84cb578ac3c8415 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.alkermes.com/20210601/role/TemplateLink" xlink:href="alks-20210601.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="alks-20210601.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>alks-8k_20210601_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="alks-20210601.xsd" xlink:type="simple"/>
    <context id="C_0001520262_20210601_20210601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001520262</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-01</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0001520262_20210601_20210601" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName contextRef="C_0001520262_20210601_20210601" id="F_000003">Alkermes plc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="C_0001520262_20210601_20210601" id="F_000004">0001520262</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0001520262_20210601_20210601" id="F_000000">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0001520262_20210601_20210601" id="F_000002">2021-06-01</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001520262_20210601_20210601" id="F_000007">L2</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0001520262_20210601_20210601" id="F_000006">001-35299</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001520262_20210601_20210601" id="F_000008">98-1007018</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001520262_20210601_20210601" id="F_000009">Connaught House</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0001520262_20210601_20210601" id="F_000010">1 Burlington Road</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0001520262_20210601_20210601" id="F_000011">Dublin 4</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="C_0001520262_20210601_20210601" id="F_000012">IE</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="C_0001520262_20210601_20210601" id="F_000013">D04 C5Y6</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001520262_20210601_20210601" id="F_000014">353</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001520262_20210601_20210601" id="F_000015">1-772-8000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0001520262_20210601_20210601" id="F_000016">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0001520262_20210601_20210601" id="F_000017">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0001520262_20210601_20210601" id="F_000018">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0001520262_20210601_20210601" id="F_000019">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="C_0001520262_20210601_20210601" id="F_000020">Ordinary shares, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001520262_20210601_20210601" id="F_000021">ALKS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001520262_20210601_20210601" id="F_000022">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001520262_20210601_20210601" id="F_000005">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140379303112792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun.  01,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Alkermes plc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001520262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1007018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Connaught House<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">1 Burlington Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dublin 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">D04 C5Y6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">1-772-8000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, $0.01 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol(s)</a></td>
<td class="text">ALKS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ +SG!4@=!36*!
ML0   !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M    "  O.<%2[1DL5.X    K @  $0              @ &O    9&]C4')O
M<',O8V]R92YX;6Q02P$"% ,4    "  O.<%2F5R<(Q &  "<)P  $P
M        @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( "\Y
MP5*4(FVN3@0  -T0   8              " @0T(  !X;"]W;W)K<VAE971S
M+W-H965T,2YX;6Q02P$"% ,4    "  O.<%2GZ ;\+$"  #B#   #0
M        @ &1#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( "\YP5*7BKL<
MP    !,"   +              "  6T/  !?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( "\YP5(ZJJ+G0 $  #P"   /              "  580  !X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    "  O.<%2)!Z;HJT   #X 0  &@
M    @ '#$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M"  O.<%299!YDAD!  #/ P  $P              @ &H$@  6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     "0 ) #X"  #R$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="alks-8k_20210601.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="alks-8k_20210601.htm">alks-8k_20210601.htm</File>
    <File>alks-20210601.xsd</File>
    <File>alks-20210601_lab.xml</File>
    <File>alks-20210601_pre.xml</File>
    <File>alks-ex991_15.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "alks-8k_20210601.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "alks-8k_20210601.htm"
     ]
    },
    "labelLink": {
     "local": [
      "alks-20210601_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "alks-20210601_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "alks-20210601.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "alks",
   "nsuri": "http://www.alkermes.com/20210601",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "alks-8k_20210601.htm",
      "contextRef": "C_0001520262_20210601_20210601",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "role": "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "alks-8k_20210601.htm",
      "contextRef": "C_0001520262_20210601_20210601",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol(s)"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.alkermes.com/20210601/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001564590-21-030940-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-030940-xbrl.zip
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M_V\$.0)7U)U/D1\ "SP%P>S,ME]>7MK>&/N<DGD@V'G;I5,;6%8"W6,(RC^
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M>+=PA(BH.81X8FBL[D<8RW23=9S*.IQC6<<'%5JPG(GYP/%T1H0J]M:EWJ%
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M0#D?:451#?>,Y-L5NU7.*GW3:0@7?4_LO_ 81^^EUUD*<D&VL2,'M+')(_A
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MI/K[;$=8RD=))29__UY*RP]X<J[< U9@=O9H]OENKI@OL_?UX[]02P,$%
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M[7UI4QM)FO#WC=C_D.N)[H58W5P"/(Z0 ;?I,9A%]'A[ODRDJE*J;*HJJ^M
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M@2?%E!U]%B 6P0I1LY<.DL(T7UR'66(C6.(APP*I!S;F$-\"X8/62T>$1$#
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M3M^D:J'^4P:X#CO$;2?9; :*M.:JQ;#MLIY3EI@3JY\Q) B1(*K0>2 H;!A
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M,MB\*A77&3ZA0:X\8]/!/.M\,TTB2:4"B]F 6UZPT2YM.0,<T1><Z$&QI-*
MB:FR0%G#(J5KB<6?F:2T3L#IB%IWZW9=5,8 Q  5BQ:[P[A87V55^04:<[<
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M8"Z9] DBL.]#PJ=BWQR3N@4BW;RD"/%T6AW&(2#X&QY*E6?>471>SC5EV$C
M1V&(R'FN;5*PWW?((_N]]C_R"UZ CL"(1QK51#@=MM%OL4%OT+,I@D 63'8R
M*'0^A38%6/]\LJB01V-E%7JDWSKC3IE9XUA'G_7-8.P84";,G=8/KYG-C8\.
MS)[6;<8T]7#.B;Z& OV2>1BWJK]81HNXK=W:$AI% N<S4U?+*Q.P9\,M30%6
MJIF(@"%#8"5DMJ4,F3SS!F43+(Z#L3L(!AF:>WU)M%5O/[F--MIS@WGX);P
M]);GN((*+4-^IZ:X,@QWI5J4NKXZE3WW^;Q5N5:L9N)S&> 5+K1Q6R-/;&NC
M2",H(%!ED:OC.>EGU/9HZXO;J#D91$V)]09!\IDJ9$^\E,?VG16-(C:'@WWM
M>8 W@?CR^-+DG9\?CR]&AZ,[6AF:O5_K4)AD4057:)_8-Q11KNWIK?0'< S
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ML804&DF[7AKX\,?_ U!+ 0(4 Q0    ( "\YP5)C)H,=K 0  +T6   1
M          "  0    !A;&MS+3(P,C$P-C Q+GAS9%!+ 0(4 Q0    ( "\Y
MP5(]@BR@(0<  $1,   5              "  =L$  !A;&MS+3(P,C$P-C Q
M7VQA8BYX;6Q02P$"% ,4    "  O.<%241"[XOX$  "/+0  %0
M    @ $O#   86QK<RTR,#(Q,#8P,5]P<F4N>&UL4$L! A0#%     @ +SG!
M4DQ*[CWN$0  >J(  !0              ( !8!$  &%L:W,M.&M?,C R,3 V
M,#$N:'1M4$L! A0#%     @ +SG!4M$W!FG@+   1 0! !$
M ( !@",  &%L:W,M97@Y.3%?,34N:'1M4$L%!@     %  4 1@$  (]0
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
